Key result
SCN5A mutations in Brugada syndrome link to ~14-fold higher odds of a large arrhythmogenic substrate.
Why the study?
Although SCN5A is the most commonly known mutated gene in Brugada syndrome, the genotype-phenotype relationship remained poorly understood and uncertain.
Does carrying a pathogenic or likely pathogenic SCN5A mutation predict a larger epicardial arrhythmogenic substrate and more severe clinical phenotype in high-risk probands with Brugada syndrome?
Cohort (n=195)
Electrophysiologists measuring arrhythmogenic substrate areas were blinded to the genetic analysis
No
Does carrying a pathogenic or likely pathogenic SCN5A mutation predict a larger epicardial arrhythmogenic substrate and more severe clinical phenotype in high-risk probands with Brugada syndrome?
This study demonstrates for the first time that pathogenic SCN5A mutations are the strongest determinant of epicardial arrhythmogenic substrate extent in Brugada syndrome, linking genetic background directly to electrophysiological phenotype severity and clinical arrhythmic risk.
Answers are grounded in this paper and cite their sources.
SCN5A status was associated with larger substrates and events in Brugada syndrome; extends genotype-phenotype links but leaves open prospective validation for risk stratification.
AIMS: Brugada syndrome (BrS) is associated with an increased risk of sudden cardiac death due to ventricular tachycardia/fibrillation (VT/VF) in young, otherwise healthy individuals. Despite SCN5A being the most commonly known mutated gene to date, the genotype-phenotype relationship is poorly understood and remains uncertain. This study aimed to elucidate the genotype-phenotype correlation in BrS. METHODS AND RESULTS: Brugada syndrome probands deemed at high risk of future arrhythmic events underwent genetic testing and phenotype characterization by the means of epicardial arrhythmogenic substrate (AS) mapping, and were divided into two groups according to the presence or absence of SCN5A mutation. Two-hundred probands (160 males, 80%; mean age 42.6 ± 12.2 years) were included in this study. Patients harbouring SCN5A mutations exhibited a spontaneous type 1 pattern and experienced aborted cardiac arrest or spontaneous VT/VF more frequently than the other subjects. SCN5A-positive patients exhibited a larger epicardial AS area, more prolonged electrograms and more frequently observed non-invasive late potentials. The presence of an SCN5A mutation explained >26% of the variation in the epicardial AS area and was the strongest predictor of a large epicardial area. CONCLUSION: In BrS, the genetic background is the main determinant for the extent of the electrophysiological abnormalities. SCN5A mutation carriers exhibit more pronounced epicardial electrical abnormalities and a more aggressive clinical presentation. These results contribute to the understanding of the genetic determinants of the BrS phenotypic expression and provide possible explanations for the varying degrees of disease expression.
No takes yet. Share an insight, caveat, or question.
Ciconte et al. (2020) conducted a cohort in Brugada syndrome (n=195). SCN5A pathogenic/likely pathogenic mutation carrier status vs. SCN5A mutation-negative status was evaluated on Large epicardial arrhythmogenic substrate area (≥6.3 cm²) (OR 14, 95% CI 5.6-35.8, p=<0.001). SCN5A mutation carriers with Brugada syndrome had a larger baseline epicardial arrhythmogenic substrate and 14 times the odds of a substrate ≥6.3 cm².
Synapse has enriched 10 related papers. Consider them for comparative context: